Kyverna Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune diseases, is planning an initial public offering to raise approximately $272.6 million for clinical development and research.
NASDAQ
Kyverna Therapeutics is seeking to raise approximately $182.3 million through an initial public offering to further the clinical development of its cell therapies for autoimmune diseases.
NASDAQ
Kyverna Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to further develop its cell therapies for autoimmune diseases, including its lead candidate KYV-101.